A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Trial Profile

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs Rilimogene galvacirepvec-rilimogene glafolivec (Primary) ; Granulocyte macrophage colony stimulating factor
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PROSPECT
  • Sponsors Bavarian Nordic; BN ImmunoTherapeutics
  • Most Recent Events

    • 12 Aug 2017 Planned End Date changed from 1 Jan 2019 to 1 Nov 2019.
    • 12 Aug 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Nov 2018.
    • 09 Aug 2017 Planned End Date changed from 1 Jun 2018 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top